Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Other financing activities (2022 - 2025)

Historic Other financing activities for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $67132.0.

  • bioAffinity Technologies' Other financing activities fell 6384.67% to $67132.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $809869.0, marking a year-over-year decrease of 1820.36%. This contributed to the annual value of $989681.0 for FY2024, which is 3216.49% up from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' Other financing activities is $67132.0, which was down 6384.67% from $211607.0 recorded in Q2 2025.
  • bioAffinity Technologies' Other financing activities' 5-year high stood at $326616.0 during Q1 2025, with a 5-year trough of $26685.0 in Q2 2022.
  • Over the past 4 years, bioAffinity Technologies' median Other financing activities value was $185687.0 (recorded in 2024), while the average stood at $171654.5.
  • Per our database at Business Quant, bioAffinity Technologies' Other financing activities skyrocketed by 53801.76% in 2023 and then crashed by 6384.67% in 2025.
  • bioAffinity Technologies' Other financing activities (Quarter) stood at $36847.0 in 2022, then soared by 536.44% to $234510.0 in 2023, then dropped by 12.79% to $204514.0 in 2024, then crashed by 67.17% to $67132.0 in 2025.
  • Its last three reported values are $67132.0 in Q3 2025, $211607.0 for Q2 2025, and $326616.0 during Q1 2025.